KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of "Buy" from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have received an average recommendation of "Buy" from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $24.83.

KALV has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Jones Trading reiterated a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV opened at $11.41 on Monday. The business has a 50 day simple moving average of $12.47 and a 200 day simple moving average of $10.93. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $15.50. The stock has a market cap of $567.31 million, a price-to-earnings ratio of -3.07 and a beta of -0.01.

Insider Activity at KalVista Pharmaceuticals

In related news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $9.42 per share, for a total transaction of $235,500.00. Following the purchase, the insider now owns 5,303,985 shares in the company, valued at $49,963,538.70. The trade was a 0.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 3,808 shares of the company's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $45,086.72. Following the sale, the chief executive officer now directly owns 293,367 shares in the company, valued at $3,473,465.28. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,899 shares of company stock worth $206,176 over the last quarter. Corporate insiders own 10.50% of the company's stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its stake in shares of KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock worth $3,923,000 after purchasing an additional 12,263 shares during the last quarter. Rhumbline Advisers grew its holdings in KalVista Pharmaceuticals by 3.4% in the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock valued at $611,000 after purchasing an additional 1,762 shares during the period. Woodline Partners LP grew its holdings in KalVista Pharmaceuticals by 25.5% in the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock valued at $18,666,000 after purchasing an additional 329,068 shares during the period. Parkman Healthcare Partners LLC acquired a new stake in shares of KalVista Pharmaceuticals in the first quarter worth approximately $8,698,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock worth $281,000 after acquiring an additional 2,939 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.